Tempest Therapeutics (TPST) Expected to Announce Quarterly Earnings on Tuesday

Tempest Therapeutics (NASDAQ:TPST) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Tempest Therapeutics Stock Down 5.5 %

Shares of Tempest Therapeutics stock opened at $0.79 on Tuesday. The stock’s fifty day moving average is $0.89 and its two-hundred day moving average is $1.02. The company has a market capitalization of $34.48 million, a PE ratio of -0.52 and a beta of -1.83. Tempest Therapeutics has a 52 week low of $0.70 and a 52 week high of $6.00.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TPST. Piper Sandler dropped their price target on Tempest Therapeutics from $8.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. William Blair reaffirmed an “outperform” rating on shares of Tempest Therapeutics in a research report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research report on Wednesday, November 13th.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.